Registry-listed formulations

Tiratricol · chembl:CHEMBL41632

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • TiratricolRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • TiratricolRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • TiratricolRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 2
1
33%
Phase 3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Active, not recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

active_not_recruiting133%
unknown133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
unknown

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

NCT05911399
completedphase_3

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

NCT05579327
active_not_recruitingphase_2

Triac Trial II in MCT8 Deficiency Patients

NCT02396459

Clinical Trials (3)

Showing 3 of 3 trials
NCT05911399

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

Unknown
NCT05579327Phase 3

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Completed
NCT02396459Phase 2

Triac Trial II in MCT8 Deficiency Patients

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
3

External References

ChEMBL
CHEMBL41632

Names & Codes

ATC Classification

H03AA04D11AX08

Research Codes

NSC-759294T3-acetic acid